Can New Drugs Help Gilead Sciences Rebound?
Gilead Sciences (NASDAQ: GILD) put up a rather lackluster third-quarter report last week. Revenue was flat year over year, dragged down by a 20% decline in sales of its hepatitis C franchise, as well as lower sales of angina drug Ranexa and pulmonary arterial hypertension drug Letairis as both drugs face generic competition.
But management at the big biotech still has high hopes of turning things around with its newer medications.
CFO Robin Washington talked about the company's CAR T drug, Yescarta, which Gilead acquired in a 2017 deal with Kite Pharma:
Source Fool.com
